R&B Denims Ltd. logo

R&B Denims Ltd. (RNBDENIMS)

Market Closed
12 Aug, 22:00
MSE MSE
8. 99
-0.02
-0.222%
- Market Cap
- P/E Ratio
- Div Yield
18,563 Volume
- Eps
9.01
Previous Close
Add Transaction
Day Range
8.9 9.15
Year Range
8.74 69.77
Want to track RNBDENIMS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

RNBDENIMS closed today lower at ₹8.99, a decrease of -0.222% from yesterday's close, completing a monthly decrease of -14.4624% or -₹1.52. Over the past 12 months, RNBDENIMS stock lost -93.53%.
RNBDENIMS is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.3071%, based on the last three reports.
R&B Denims Ltd. has completed 2 stock splits, with the recent split occurring on Apr 02, 2026.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

RNBDENIMS Chart

R&B Denims Ltd. (RNBDENIMS) FAQ

What is the stock price today?

The current price is ₹8.99.

On which exchange is it traded?

R&B Denims Ltd. is listed on MSE.

What is its stock symbol?

The ticker symbol is RNBDENIMS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has R&B Denims Ltd. ever had a stock split?

R&B Denims Ltd. had 2 splits and the recent split was on Apr 02, 2026.

R&B Denims Ltd. Profile

Textiles, Apparel & Luxury Goods Industry
Consumer Discretionary Sector
Sascha Knoche CEO
MSE Exchange
INE012Q01021 ISIN
Germany Country
39 Employees
- Last Dividend
2 Apr 2026 Last Split
- IPO Date

Overview

Arzneiwerk AG VIDA is a pioneering pharmaceutical company situated in Berlin, Germany, renowned for its dedicated efforts in supplying medications for newly developed or rare diseases across Europe. Initially known as TELES Aktiengesellschaft, the company underwent a significant transformation, adopting its current name in July 2024. This strategic rebranding marked a pivotal shift towards focusing exclusively on the unique challenges and requirements associated with rare and newly discovered medical conditions. Arzneiwerk AG VIDA’s mission is underpinned by a strong commitment to innovating within the pharmaceutical landscape, ensuring that those in need have access to critical, life-saving medicines.

Products and Services

Arzneiwerk AG VIDA’s product and service portfolio is meticulously designed to address the complex needs of patients suffering from rare and newly identified diseases. Each offering is characterized by a focus on innovation, accessibility, and effectiveness.

  • Supply of Pharmaceuticals for Rare Diseases:
  • This service focuses on the sourcing and distribution of drugs for rare diseases, a critical area often overlooked by larger pharmaceutical companies. Arzneiwerk AG VIDA collaborates with research institutions and healthcare providers to ensure these vital medications are accessible to those in need.

  • Newly Developed Medicines:
  • Understanding the importance of innovation in healthcare, Arzneiwerk AG VIDA also specializes in the distribution of recently developed drugs. This includes medicines that have just passed clinical trials and received approval for public use, offering hope and new solutions for patients with complex health issues.

Contact Information

Address: Ordensmeisterstr. 15-16
Phone: 49 30 399 28 00